Article Details

GSK Receives $370 Million Upfront Settlement in CureVac/BioNTech mRNA Patent Litigation

Retrieved on: 2025-08-08 13:54:18

Tags for this article:

Click the tags to see associated articles and topics

GSK Receives $370 Million Upfront Settlement in CureVac/BioNTech mRNA Patent Litigation. View article details on hiswai:

Excerpt

... BioNTech and Pfizer. The payment is due to GSK's existing license agreement with CureVac. The settlement also includes a reduction in royalties ...

Article found on: www.ainvest.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo